Compare MOH & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | TECH |
|---|---|---|
| Founded | 1980 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.6B |
| IPO Year | 2002 | 1995 |
| Metric | MOH | TECH |
|---|---|---|
| Price | $183.24 | $50.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $167.00 | $71.82 |
| AVG Volume (30 Days) | 791.3K | ★ 3.3M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.27 | ★ 0.81 |
| Revenue | ★ $45,426,000,000.00 | $1,219,635,000.00 |
| Revenue This Year | $2.40 | $2.49 |
| Revenue Next Year | $5.18 | $6.40 |
| P/E Ratio | $644.81 | ★ $63.53 |
| Revenue Growth | ★ 11.75 | 5.23 |
| 52 Week Low | $121.06 | $43.20 |
| 52 Week High | $311.53 | $72.16 |
| Indicator | MOH | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 52.62 |
| Support Level | $175.83 | $49.98 |
| Resistance Level | $184.83 | $57.86 |
| Average True Range (ATR) | 6.17 | 2.02 |
| MACD | -2.28 | 0.80 |
| Stochastic Oscillator | 47.98 | 85.39 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.